1. Home
  2. GENK vs GRCE Comparison

GENK vs GRCE Comparison

Compare GENK & GRCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GENK
  • GRCE
  • Stock Information
  • Founded
  • GENK 2011
  • GRCE 2002
  • Country
  • GENK United States
  • GRCE United States
  • Employees
  • GENK N/A
  • GRCE N/A
  • Industry
  • GENK Restaurants
  • GRCE
  • Sector
  • GENK Consumer Discretionary
  • GRCE
  • Exchange
  • GENK Nasdaq
  • GRCE NYSE
  • Market Cap
  • GENK 27.9M
  • GRCE 32.1M
  • IPO Year
  • GENK 2023
  • GRCE N/A
  • Fundamental
  • Price
  • GENK $5.65
  • GRCE $2.29
  • Analyst Decision
  • GENK Strong Buy
  • GRCE Strong Buy
  • Analyst Count
  • GENK 3
  • GRCE 1
  • Target Price
  • GENK $12.17
  • GRCE $12.00
  • AVG Volume (30 Days)
  • GENK 206.0K
  • GRCE 34.0K
  • Earning Date
  • GENK 03-06-2025
  • GRCE 02-13-2025
  • Dividend Yield
  • GENK N/A
  • GRCE N/A
  • EPS Growth
  • GENK 62.05
  • GRCE N/A
  • EPS
  • GENK 0.13
  • GRCE N/A
  • Revenue
  • GENK $208,380,000.00
  • GRCE N/A
  • Revenue This Year
  • GENK $20.99
  • GRCE N/A
  • Revenue Next Year
  • GENK N/A
  • GRCE N/A
  • P/E Ratio
  • GENK $44.87
  • GRCE N/A
  • Revenue Growth
  • GENK 15.12
  • GRCE N/A
  • 52 Week Low
  • GENK $5.00
  • GRCE $2.13
  • 52 Week High
  • GENK $14.46
  • GRCE $4.97
  • Technical
  • Relative Strength Index (RSI)
  • GENK 47.16
  • GRCE N/A
  • Support Level
  • GENK $5.30
  • GRCE N/A
  • Resistance Level
  • GENK $7.41
  • GRCE N/A
  • Average True Range (ATR)
  • GENK 0.59
  • GRCE 0.00
  • MACD
  • GENK 0.08
  • GRCE 0.00
  • Stochastic Oscillator
  • GENK 26.97
  • GRCE 0.00

About GENK GEN Restaurant Group Inc.

GEN Restaurant Group Inc is an Asian casual dining restaurant in the United States. It offers an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables.

About GRCE GRACE THERAPEUTICS INC

Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.

Share on Social Networks: